Current state of agonist radioligands for imaging of brain dopamine D2/D3 receptors in vivo with positron emission tomography
- PMID: 20583987
- DOI: 10.2174/156802610793176837
Current state of agonist radioligands for imaging of brain dopamine D2/D3 receptors in vivo with positron emission tomography
Abstract
Dopamine (DA) is known to play an important role in numerous brain functions and has been suggested to be involved in several neuropsychiatric and neurological disorders. From early on, positron emission tomography (PET) studies of the DA system have yielded high interest. Currently, several aspects of the functionality of DA neurons can be imaged, including the DA synthesis rate and the expression of DA-related proteins (receptors and transporters). A more recent application of radioligands targeting DA receptors is to study the endogenous neurotransmitter levels in vivo in brain. In vitro binding studies have suggested that in general DA receptors, as many other G-protein coupled receptors, exist in two affinity states for agonist binding. The high affinity state is thought to represent the functional state of the receptor, and the proportion between high and low affinity states may change with the development of disease. PET imaging with agonist radioligands may provide information on the existence of the high affinity state in vivo. In addition, DA receptor agonist radioligands may be superior tools for measuring changes in endogenous DA levels as antagonist radioligands inherently bind to both the low and the high affinity state. This review primarily summarizes the present status of the D(2)/D(3) receptor agonist PET radioligands. In addition several PET studies evaluating the utility of the agonist concept are discussed.
Similar articles
-
Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA.Synapse. 2008 Oct;62(10):756-63. doi: 10.1002/syn.20549. Synapse. 2008. PMID: 18651641 Free PMC article.
-
Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA.Synapse. 2009 May;63(5):378-89. doi: 10.1002/syn.20615. Synapse. 2009. PMID: 19173265
-
Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain.Synapse. 2016 Nov;70(11):453-60. doi: 10.1002/syn.21920. Epub 2016 Jul 11. Synapse. 2016. PMID: 27341789 Free PMC article.
-
Selectivity of probes for PET imaging of dopamine D3 receptors.Neurosci Lett. 2019 Jan 19;691:18-25. doi: 10.1016/j.neulet.2018.03.006. Epub 2018 Mar 5. Neurosci Lett. 2019. PMID: 29518538 Free PMC article. Review.
-
Challenges in the development of dopamine D2- and D3-selective radiotracers for PET imaging studies.J Labelled Comp Radiopharm. 2018 Mar;61(3):291-298. doi: 10.1002/jlcr.3558. Epub 2017 Sep 26. J Labelled Comp Radiopharm. 2018. PMID: 28857231 Review.
Cited by
-
Development and In Vivo Evaluation of a κ-Opioid Receptor Agonist as a PET Radiotracer with Superior Imaging Characteristics.J Nucl Med. 2019 Jul;60(7):1023-1030. doi: 10.2967/jnumed.118.220517. Epub 2019 Jan 10. J Nucl Med. 2019. PMID: 30630942 Free PMC article.
-
(18)F-MCL-524, an (18)F-Labeled Dopamine D2 and D3 Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study.J Nucl Med. 2014 Jul;55(7):1164-70. doi: 10.2967/jnumed.113.133876. Epub 2014 May 1. J Nucl Med. 2014. PMID: 24790219 Free PMC article.
-
Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain.Int J Neuropsychopharmacol. 2017 Sep 1;20(9):683-691. doi: 10.1093/ijnp/pyx051. Int J Neuropsychopharmacol. 2017. PMID: 28911007 Free PMC article.
-
Exploring the relationship between social attachment and dopamine D2/3 receptor availability in the brains of healthy humans using [11C]-(+)-PHNO.Soc Neurosci. 2017 Apr;12(2):163-173. doi: 10.1080/17470919.2016.1152997. Epub 2016 Feb 29. Soc Neurosci. 2017. PMID: 26873034 Free PMC article.
-
The High Affinity Dopamine D2 Receptor Agonist MCL-536: A New Tool for Studying Dopaminergic Contribution to Neurological Disorders.ACS Chem Neurosci. 2021 Apr 21;12(8):1428-1437. doi: 10.1021/acschemneuro.1c00094. Epub 2021 Apr 12. ACS Chem Neurosci. 2021. PMID: 33844498 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources